Skip to content
drillr.ai

ROG

Rogers Corporation

NYSE · USTechnologyHardware, Equipment & Parts
$130.82-1.07%

Price as of Jul 20, 2026

ROG news

Rogers Corporation news

A server-rendered, paginated timeline of the latest available company news.

  1. Rogers Corporation Releases Its 2026 Sustainability Report

    Rogers Corporation Releases Its 2026 Sustainability Report Rogers Corporation (NYSE: ROG) today released its 2026 Sustainability Report, outlining Rogers’ approach to managing environmental impacts, supporting employees, maintaining strong governance practices, and developing advanced materials that help customers improve efficiency and enable next-generation technologies. “We are pleased to share our 2026 Sustainability Report,” said Ali El-Haj, Rogers President and Chief Executive Officer. “

    Business Wire ·

  2. Rogers Corporation Schedules Second Quarter 2026 Earnings Call for July 28

    Rogers Corporation Schedules Second Quarter 2026 Earnings Call for July 28 Rogers Corporation (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.rogerscorp.com%2F&esheet=54570376&newsitemid=20260714474498&lan=en-US&anchor=Rogers+Corporation&index=1&md5=9233316c6231157b2728434fd78be444) (NYSE:ROG) (“Rogers”) plans to announce second quarter 2026 results on July 28, 2026 after market close, which will be followed by a conference call at 5:00 pm ET. The call will be hosted by Al

    Business Wire ·

  3. Rogers Corporation Announces Addition of Brett Cope and Eric Starkloff to Its Board of Directors

    Rogers Corporation Announces Addition of Brett Cope and Eric Starkloff to Its Board of Directors Rogers Corporation (NYSE: ROG) (“Rogers”) announced today that Brett Cope and Eric Starkloff were elected to the Company’s Board of Directors. Both Mr. Cope and Mr. Starkloff bring extensive executive leadership experience and deep expertise in highly relevant markets. “The Board remains committed to unlocking higher levels of growth and profitability at Rogers,” said Armand Lauzon, Chair of the Bo

    Business Wire ·

  4. Rogers Corporation Reports First Quarter 2026 Results

    Rogers Corporation Reports First Quarter 2026 Results * Net sales of $200.5 million increased 5.2% year-over-year (YoY) * Gross margin of 32.2% increased 230 basis points YoY * Net income of $4.5 million increased by $5.9 million YoY * Adjusted EBITDA of $32.0 million increased by $12.5 million YoY * Diluted earnings per share of $0.25 increased by $0.33 YoY * Adjusted earnings per share of $0.75 increased by $0.48 YoY Rogers Corporation (NYSE:ROG) today announced financial results

    Business Wire ·

  5. Rogers Corporation Schedules First Quarter 2026 Earnings Call for April 28

    Rogers Corporation Schedules First Quarter 2026 Earnings Call for April 28 Rogers Corporation (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.rogerscorp.com%2F&esheet=54500214&newsitemid=20260413001480&lan=en-US&anchor=Rogers+Corporation&index=1&md5=aad8eff78ed5b3c616cd7798fab2c72e) (NYSE:ROG) (“Rogers”) plans to announce first quarter 2026 results on April 28, 2026 after market close, which will be followed by a conference call at 5:00 pm ET. The call will be hosted by Al

    Business Wire ·

  6. Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease

    Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease PR Newswire BASEL, Switzerland, March 16, 2026 * The Elecsys ApoE4 test is the first CE marked in-vitro diagnostic immunoassay to identify individuals carrying the ApoE4 genetic variant using a simple blood sample. * The test offers a fast, reliable and accessible option to rapidly differentiate between carriers and non-c

    PR Newswire ·

  7. Roche Annual General Meeting 2026

    * Shareholders approved all proposals of the Board of Directors * Severin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed * 39th consecutive dividend increase to CHF 9.80 per share * Exchange of non-voting equity securities (Genussscheine) for Participation Certificates approved Basel, 10 March 2026 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders approved all proposals of the Board of Directors at it

    Globe Newswire ·

  8. Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

    Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer * persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed * Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment * Genentech is committed to transforming ER-positive breast cancer care, anchore

    Business Wire ·

  9. [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer

    * persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed * Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment * Roche is committed to transforming ER-positive breast cancer care, anchored by the landmark success of lidERA in early-stage disease and evERA in the advanced setting(1,2)

    Globe Newswire ·

  10. New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

    New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus * Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms * Gazyva has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE) * If approved, Gazyva would be the first Type

    Business Wire ·

  11. New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus

    * Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms * Gazyva/Gazyvaro has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE) * If approved, Gazyva/Gazyvaro would be the first Type II anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity(1) * SLE is a potentially life-

    Globe Newswire ·

  12. Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity

    Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity – Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value<0.001) while demonstrating placebo-like tolerability – – At the maximally effective dose, there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events – – The data support further development of petrelintide in

    Business Wire ·

  13. Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

    * Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value<0.001) while demonstrating placebo-like tolerability * At the maximally effective dose, there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events * The data support further development of petrelintide in chronic weight management as monotherapy and its tolerability profile also confirms its value as a combination partner Basel, 05 March 2026 -

    Globe Newswire ·

  14. New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools

    New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools PR Newswire BASEL, Switzerland, March 5, 2026 * Global survey of 4,326 people with diabetes shows how the unpredictability and mental burden associated with managing the condition negatively impacts daily life.(1) * Majority of respondents say that constantly planning around blood glucose levels, meal times, and medication schedules interfere with routine activities

    PR Newswire ·

  15. Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

    Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1) - FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with FENhance 2 results showing 59% reduction - - FENhance 1 is the final study readout of the fenebrutinib pivotal clinical development progr

    Business Wire ·

  16. [Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)

    * FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with FENhance 2 results showing 59% reduction * FENhance 1 is the final study readout of the fenebrutinib pivotal clinical development programme in MS, following positive results for FENhance 2 in RMS and for FENtrepid in primary progressive multiple sclerosis (PPMS) * Fenebrutinib has the potential to become

    Globe Newswire ·